Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Effect of Intravitreal Injection of Erythropoietin in Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy



Dehghani A1 ; Ghanbari H1 ; Kamani M2 ; Raie M3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Ophthalmology, School of Medicine and Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Ophthalmology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Isfahan Medical School Published:2017

Abstract

Background: Nonarteritic anterior ischemic optic neuropathy (NA-AION) is a disease with serious complications that already does not have any standard treatment. Some studies and experiences had shown that intravitreal erythropoietin injection has a neuroprotective effect. But there are some different and inconsistent results in those studies. So, the aim of this study was determining the effect of intravitreal injection of erythropoietin in treatment of the disease. Methods: In a clinical trial study, 40 eyes (from 38 patients) were selected and randomly divided in two groups. In the first group, 2000 IU erythropoietin was injected in vitreous and the second group did not receive erythropoietin. Visual acuity and visual field were measured before and three months after the treatment and compared between the two groups. Findings: The mean visual acuity was improved in the treatment group (P < 0.001) but did not differed in the control group (P = 0.270). In addition, the pattern standard deviation was improved in the treatment group (P = 0.047) but did not statistically change in the control group (P = 0.130). Conclusion: Intravitreal injection of erythropoietin in patients with nonarteritic anterior ischemic optic neuropathy leads to remarkable and significant improvement of visual acuity and field 3 months after the injection. So, this treatment strategy is advised in patients with suitable condition and without any contraindication by ophthalmologists. To evaluate the long-term effects, further studies are recommended. © 2017, Isfahan University of Medical Sciences(IUMS). All rights reserved.
Related Docs
View other Related Docs
1. Therapeutic Effect of Posterior Sub-Tenon Methyl Prednisolone in Anterior Ischemic Optic Neuropathy: A Randomized Clinical Trial, Iranian Journal of Ophthalmology (2011)
2. A Double-Blind, Placebo-Controlled Trial of Adding Erythropoietin to Intravenous Methylprednisolone for the Treatment of Unilateral Acute Optic Neuritis of Unknown or Demyelinative Origin, Graefe's Archive for Clinical and Experimental Ophthalmology (2015)
3. The Effect of Hesa-A (Natural Drug) on Visual Acuity in Age Related Macular Degeneration: A Randomized Double Blind Controlled Clinical Trial, African Journal of Traditional, Complementary and Alternative Medicines (2009)
4. Ocular Manifestations in Hemodialysis Patients: Importance of Ophthalmic Examination in Prevention of Ocular Sequels, International Journal of Preventive Medicine (2019)
5. Color Blindness Among Multiple Sclerosis Patients in Isfahan, Journal of Research in Medical Sciences (2012)
6. Evaluation of Intravitreal Injection of Bevacizumab (Avastin) in Treatment of Diabetic Macular Edema, Journal of Research in Medical Sciences (2012)
7. Effects of Subthreshold Diode Micropulse Laser Photocoagulation on Treating Patients With Refractory Diabetic Macular Edema, Journal of Current Ophthalmology (2019)
8. Neuroprotective Effects of Erythropoietin in Acute Ischemic Stroke, International Journal of Preventive Medicine (2013)
Experts (# of related papers)
View all Related Experts
Farzan Kianersi (6)
Mohsen Pourazizi (5)
Other Related Docs
9. Comparative Analysis of Optical Coherence Tomography Angiography (Octa) Results Between Behcet’S Disease Patients and a Healthy Control Group, Clinical Rheumatology (2024)
10. Acetazolamide and Bevacizumab Combination Therapy Versus Bevacizumab Monotherapy in Macular Edema Secondary to Retinal Vein Occlusion; [Traitement Combine Par Acetazolamide Et Bevacizumab Par Rapport a La Monotherapie Par Bevacizumab Dans L’Oedeme Maculaire Secondaire a Une Occlusion Veineuse Retinienne], Journal Francais d'Ophtalmologie (2023)
11. Combination of Intravitreal Bevacizumab and Topical Dorzolamide Versus Intravitreal Bevacizumab Alone for Diabetic Macular Edema: A Randomized Contralateral Clinical Trial, BioMed Research International (2020)
12. The Effect of Posterior Versus Anterior Subtenon Injection of Triamcinolone on Intraocular Pressure in Eyes With Retinal Vein Occlusion, Iranian Journal of Ophthalmology (2012)
13. Intravitreal Bevacizumab Versus Ranibizumab: Effects on the Vessels of the Fellow Non-Treated Eye, Journal of Current Ophthalmology (2019)
14. Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2B Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study, Cornea (2017)
15. Intravitreal Fasudil Monotherapy for Treatment of Refractory Diabetic Macular Edema: A Prospective Interventional Case Series; [Monotherapie Intravitreenne Par Fasudil Pour Le Traitement De L’Oedeme Maculaire Diabetique Refractaire : Une Serie De Cas Interventionnels Prospectifs], Journal Francais d'Ophtalmologie (2023)
16. Effects of Propranolol in Patients With Central Serous Chorioretinopathy, Journal of Research in Medical Sciences (2008)
17. Intravitreal Injections of Bevacizumab Plus Methotrexate Versus Bevacizumab Alone for the Treatment of Diabetic Macular Edema: A Randomized, Sham-Controlled Trial, Journal of Current Ophthalmology (2020)
18. Intravitreal Diclofenac Plus Bevacizumab Versus Bevacizumab Alone in Treatment-Naive Diabetic Macular Edema: A Randomized Double-Blind Clinical Trial, International Ophthalmology (2017)